A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants
Status:
Completed
Trial end date:
2021-07-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence of an intravenous (IV)
administration of the guselkumab formulation using UltraSafe Plus Passive Needle Guard
(PFS-U) to create the IV solution versus the guselkumab formulation using Final Vialed
Product (FVP) (IV) to create the IV solution.